Skip to main content

Table 3 Multivariable analysis of prognostic factors

From: Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

 

PFS

OS

HR

95% CI

P value

HR

95% CI

P value

ECOG PS

      

  2/3 versus 0/1 (Ref)

2.27

1.25–4.10

0.007

-

-

-

Primary site

      

  GEJ versus Stomach (Ref)

-

-

-

-

-

-

Weight loss

      

  Yes versus No (Ref)

1.67

1.21–2.28

0.001

1.46

1.04–2.01

0.030

Peritoneal seeding

      

  Yes versus No (Ref)

-

-

-

1.76

1.10–2.80

0.019

MSI/MMR status

      

  MSI-H/dMMR versus others (Ref)

0.23

0.10–0.53

0.001

0.03

0.004–0.21

< 0.001

Serum sodium, mEq/L

      

  < 135 versus ≥ 135 (Ref)

-

-

-

1.92

1.24–2.96

0.003

Serum albumin, g/dL

      

  < 3.5 versus ≥ 3.5 (Ref)

-

-

-

1.78

1.19–2.66

0.005

Duration of 2nd line therapya

      

  <median versus ≥ median (Ref)

-

-

-

2.17

1.53–3.08

< 0.001

  1. Abbreviations: PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; Ref, reference; ECOG, Eastern Cooperative Oncology Group; PS, performance status; GEJ, gastroesophageal junction; MSI/MMR, microsatellite instability/mismatch repair
  2. aThe median duration of 2nd line treatment was 3.7 months
  3. *Univariable analyses included potential prognostic factors for predicting survival associated with ICI; age, ECOG PS, weight loss in the previous 3 months, presence of liver metastasis, presence of peritoneal metastasis, prior gastrectomy, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), serum sodium, serum albumin, primary site, duration of 2nd line paclitaxel/ramucirumab treatment, MSI/MMR status, HER2 status, EBV status
  4. **Multivariable analysis was performed using a backward selection method for factors that showed significant results in the univariable analyses